NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ:...
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024 NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the...
Cellectis publiera ses résultats financiers du troisième trimestre 2024 le 4 novembre 2024 NEW YORK, 30 oct. 2024 (GLOBE NEWSWIRE) -- Cellectis...
Cellectis présentera des données sur des TALE Base Editors ainsi que sur son programme de thérapie génique non-virale lors du 31ème congrès annuel...
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:...
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress NEW YORK, Oct. 22, 2024 (GLOBE...
Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social (Article 223-16 du Règlement Général de...
Monthly information on share capital and company voting rights (Article 223-16 of General Regulation of the French financial markets...
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety NEW YORK, Sept. 03...
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:...
Cellectis présente des preuves précliniques de l’efficacité des cellules CAR T MUC1 contre le cancer du sein triple négatif tout en préservant la...
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors NEW YORK, Aug. 26...
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ:...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads